Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H13N3O.H3O4P |
| Molecular Weight | 277.2142 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.CC(C)NNC(=O)C1=CC=NC=C1
InChI
InChIKey=YPDVTKJXVHYWFY-UHFFFAOYSA-N
InChI=1S/C9H13N3O.H3O4P/c1-7(2)11-12-9(13)8-3-5-10-6-4-8;1-5(2,3)4/h3-7,11H,1-2H3,(H,12,13);(H3,1,2,3,4)
| Molecular Formula | C9H13N3O |
| Molecular Weight | 179.219 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H3O4P |
| Molecular Weight | 97.9952 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy. Iproniazid is no longer clinically prescribed and has been withdrawn due to incidences of hepatotoxicity.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P21397 Gene ID: 4128.0 Gene Symbol: MAOA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21200377 |
|||
Target ID: P27338 Gene ID: 4129.0 Gene Symbol: MAOB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21200377 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Marsilid Approved UseDepression Launch Date1951 |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014-01 |
|
| [Depression in the elderly. Medical treatment]. | 2001-02-24 |
|
| Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. | 1985-09-01 |
|
| Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics. | 1984-04 |
|
| Effects of a hydrazine monoamine oxidase inhibitor (phenelzine) on isoproterenol-induced myocardiopathies in the rat. | 1967-09 |
|
| The chemical approach to the control of tuberculosis. | 1952-08-08 |
Sample Use Guides
50 patients with depression who had been considered suitable for E.C.T. were given iproniazid in doses up to 450 mg/day for periods varying from two to forty weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7340462
MItochondrial fractions were isolated from bovine tissue homogenates of bovine brain and suspended in 0.1 M phosphate buffer (pH 7.4). Mitochondrial fractions were pre-incubated with 5-HT (1 mM), 2-phenylethylamine
(0.8 mM), tyramine (3.2 mM), dopamine (3 mM) or Hi (10
mM) at 37 deg-C for 30 - 45 minutes. Bovine mitochondrial were further incubated with increasing concentrations of Iproniazid (0.001 to 0.1 mM) which caused gradual inhibition of the deamination of 5-HT, tyramine, and dopamine. At 1 mM of Iproniazid, there was a marked increase in HDA, which was quite small in the mitochondria not treated with Iproniazid. Treatment of bovine brain mitochondria with 1 mM Iproniazid did not induce the appearance of HDA if the catalytic sites of the MAO-A were blocked by clorgyline. A selective inhibitor of the MAO-B deprenyl did not prevent the appearance of HDA after treatment with Iproniazid.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:07:04 GMT 2025
by
admin
on
Mon Mar 31 19:07:04 GMT 2025
|
| Record UNII |
8DE00V62TV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9367
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
8DE00V62TV
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
206-164-1
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
DBSALT002894
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
305-33-9
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
m6392
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | Merck Index | ||
|
81850
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
100000128453
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
SUB35494
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY | |||
|
DTXSID20952815
Created by
admin on Mon Mar 31 19:07:04 GMT 2025 , Edited by admin on Mon Mar 31 19:07:04 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |